
Opinion|Videos|March 13, 2025
Counseling Patients About Pharmacologic Therapy for Menopausal Symptoms
Panelists discuss how health care professionals develop personalized menopause management strategies by comprehensively assessing individual medical history, symptom profiles, lifestyle factors, and potential risks. Through transparent, collaborative counseling, they guide patients in making informed decisions about pharmacologic therapies, prioritizing personalized care and holistic well-being.
Advertisement
Video content above is prompted by the following:
- What factors do you consider when developing a personalized strategy for managing menopause symptoms for a patient?
- What counseling strategies do you use to help patients make informed decisions about pharmacologic therapies for menopause symptoms? How do you counsel patients about the risks and benefits of therapy?
Advertisement
Related to this article

In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses what the hospitalization findings mean for patients and why they should be viewed as supportive evidence

Emergency and ICU pharmacists would be most likely to see pneumonic plague. An expert reviews first-line agents, alternatives, and postexposure prophylaxis.

A former residency program director unpacks why this debate keeps resurfacing, and why some reasons people give for skipping residency may not hold up the way they think they do.

The FDA approval of pritelivir offers an oral treatment for refractory HSV lesions in immunocompromised adults, with drug interactions creating an important role for pharmacists.

Weltruza, the first subcutaneous long-acting injectable (LAI) formulation of olanzapine, requires no loading doses, oral supplementation, or postinjection monitoring.

Eric Lawitz, MD, explains how pharmacists can raise liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.

Sometimes, a breakthrough matters not only because of what it does for patients today, but because of what it makes possible for tomorrow.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pneumonic Plague: What Pharmacists Need to Know About Treatment
2
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
3
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised Adults
4
Could Cemdisiran Keep Patients With Myasthenia Gravis Out of the Hospital?
5


